Snug, Did you listen to PN's talk? I did not see the number 9 patients on the slides, I listen and compared what PN said (50 or 50+ patients) with the slides to arrive at the number 9. We had 41 evaluable patients at the end of the combination safety cohorts. See my post #3060.
No one ever said DNAbilize would replace numerous cancer drugs. DNAbilize is NOT a cancer drug. It is our "neutral" lipid delivery system that contains our drugs, prexigebersen and BP-1002. It may have applications for many types of drugs and diseases not just cancer, as BPTH has already disclosed. Check out slide 4, UT Southwestern is studying DNAbilize for lupus and Thomas Jefferson U for autoimmune treatment. These applications would not include our drugs but use DNAbilize to transport other drugs.
You should research other "positively" charged lipid delivery systems for antisense drugs and RNAi. You will find that many drugs are terminated due to side effects caused, IMO, by this type of delivery system. DNAbilize's "neutrally" charged lipid delivery has ZERO side effects (to date) !
I read the BPTH CML patient slide differently from you. The patient appears to have stabilized and was removed from treatment with prexigebersen. There is no indication he died either as the result of prexigebersen or DNAbilize. If so, that would have to be reported.
In summary, management has been the issue with BPTH. To date I have seen no evidence to question the science.
